Wells Fargo lowered the firm’s price target on Q32 Bio (QTTB) to $15 from $16 and keeps an Equal Weight rating on the shares. While bempi’s recent AAD update offered additional color, “the jury is still out on bempi’s competitiveness in alopecia areata until we see more data,” the firm says. Wells remains on the sidelines for now.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio Inc’s Intellectual Property Challenges: Navigating Risks and Competitive Pressures
- Q32 Bio Reports Promising Trial Results and Financials
- Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart
- Cautious Optimism: Q32 Bio’s Strategic Shift to Focus on Bempikibart for Alopecia Areata
- IBM initiated, Southwest upgraded: Wall Street’s top analyst calls
Questions or Comments about the article? Write to editor@tipranks.com